Desmopressin 25 and 50 μg oral lyophilisates in nocturia due to idiopathic nocturnal polyuria in adults: a profile of its use

Compliance with ethical standards

Funding: The preparation of this review was not supported by any external funding.

Conflict of interest: K. A. Lyseng-Williamson is a salaried employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.

Additional information about this Adis Drug Review can be found here.

Abstract

Desmopressin 25 and 50 μg oral lyophilisates (hereafter Noqdirna®/Nocdurna®) are a new rapid-dispersing formulation of desmopressin that is indicated for the symptomatic treatment of nocturia due to nocturnal polyuria in adults of all ages. Noqdirna®/Nocdurna® is administered by placing the lyophilisate under the tongue until it dissolves, and provides greater absorption and bioavailability, as well as a more predictable pharmacokinetic profile, than standard oral desmopressin tablets, allowing lower desmopressin dosages to be used to achieve the same clinical outcomes. As responses to desmopressin differ by gender, dosages of Noqdirna®/Nocdurna® are also gender specific (25 μg in women and 50 μg in men). These dosages effectively reduced the number of nocturnal voids and increased the time to first nocturnal void in patients with nocturia, leading to improvements in sleep and nocturia-related quality of life. The use of desmopressin is associated with a risk of hyponatraemia; however, the risk is lower when lower dosages, such as 25 and 50 μg, are used. To further reduce the risk of hyponatraemia, gender-specific dosages of Noqdirna®/Nocdurna® should be used and serum sodium levels monitored appropriately before and during treatment. Access to the full article can be found here.

© Springer International Publishing AG, part of Springer Nature 2018